RIBOMIC, Inc. has announced that the first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.
Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients. A significant portion of these patients, however, exhibit incomplete response to therapy, and over the extended management course can lose vision, with the formation of submacular fibrosis (scarring) as one risk factor.
RBM-007 is a dual-action drug designed to block blood vessel growth (angiogenesis) and to block fibroblast growth factor 2 (FGF2), which causes scarring. This holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD.
A Phase 2 Study assessing the safety, efficacy and durability of RBM-007 is underway. For information about the trial, see: https://clinicaltrials.gov/ct2/show/NCT04200248